Looweihao personal page - To The Moon

Looweihao

No personal profile

1Follow

0Followers

0Topic

0Badge

2021-03-23

Wow

Sorry, the original content has been removed

2021-03-23

Nice

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3579234903697937","uuid":"3579234903697937","gmtCreate":1616142048643,"gmtModify":1616142048643,"name":"Looweihao","pinyin":"looweihao","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":353847825,"gmtCreate":1616486676567,"gmtModify":1704794701004,"author":{"id":"3579234903697937","authorId":"3579234903697937","name":"Looweihao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579234903697937","authorIdStr":"3579234903697937"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/353847825","repostId":"1178315649","repostType":4,"repost":{"id":"1178315649","kind":"news","pubTimestamp":1616486193,"share":"https://ttm.financial/m/news/1178315649?lang=&edition=fundamental","pubTime":"2021-03-23 15:56","market":"us","language":"en","title":"U.S. health agency casts doubt over AstraZeneca’s Covid vaccine trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=1178315649","media":"cnbc","summary":"KEY POINTS\n\nThe Data Safety Monitoring Board “expressed concern that AstraZeneca may have included o","content":"<div>\n<p>KEY POINTS\n\nThe Data Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial,” the U.S. National Institute of Allergy and Infectious Diseases...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/23/covid-us-health-agency-casts-doubt-over-astrazeneca-vaccine-data.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. health agency casts doubt over AstraZeneca’s Covid vaccine trial data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. health agency casts doubt over AstraZeneca’s Covid vaccine trial data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-23 15:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/03/23/covid-us-health-agency-casts-doubt-over-astrazeneca-vaccine-data.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nThe Data Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial,” the U.S. National Institute of Allergy and Infectious Diseases...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/23/covid-us-health-agency-casts-doubt-over-astrazeneca-vaccine-data.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN.UK":"阿斯利康制药","AZN":"阿斯利康"},"source_url":"https://www.cnbc.com/2021/03/23/covid-us-health-agency-casts-doubt-over-astrazeneca-vaccine-data.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1178315649","content_text":"KEY POINTS\n\nThe Data Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial,” the U.S. National Institute of Allergy and Infectious Diseases said in a statement.\nThe NIAID is led by White House Chief Medical Advisor Dr. Anthony Fauci and is part of the National Institutes of Health.\n\nLONDON — A U.S. health agency on Tuesday expressed concern that AstraZeneca may have included outdated information from a clinical trial of its Covid-19 vaccine, potentially casting doubt over published efficacy results.\nThe Data Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” the U.S. National Institute of Allergy and Infectious Diseases said in a statement.\n“We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”\nThe NIAID is led by White House Chief Medical Advisor Dr. Anthony Fauci and is part of the National Institutes of Health.\nAstraZeneca did not immediately respond to a CNBC request for comment.\nThe statement comes just one day after the findings of a large U.S. trial had shown that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization.\nData from the late-stage human trial study reaffirmed that the Oxford-AstraZeneca vaccine is safe and highly effective. The findings were welcomed as “good news for the global community.”\nThe Oxford-AstraZeneca vaccine had been temporarily suspended in several countries after reports of blood clots in some vaccinated people. However, AstraZeneca said Monday that the independent DSMB had found no increased risk of blood clots.","news_type":1},"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":353847036,"gmtCreate":1616486655625,"gmtModify":1704794700195,"author":{"id":"3579234903697937","authorId":"3579234903697937","name":"Looweihao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579234903697937","authorIdStr":"3579234903697937"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/353847036","repostId":"1185818116","repostType":4,"isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":353847825,"gmtCreate":1616486676567,"gmtModify":1704794701004,"author":{"id":"3579234903697937","authorId":"3579234903697937","name":"Looweihao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579234903697937","idStr":"3579234903697937"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/353847825","repostId":"1178315649","repostType":4,"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":353847036,"gmtCreate":1616486655625,"gmtModify":1704794700195,"author":{"id":"3579234903697937","authorId":"3579234903697937","name":"Looweihao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579234903697937","idStr":"3579234903697937"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/353847036","repostId":"1185818116","repostType":4,"isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}